2017 Q4 Form 10-Q Financial Statement
#000114420417057789 Filed on November 09, 2017
Income Statement
| Concept | 2017 Q4 | 2017 Q3 | 2016 Q4 |
|---|---|---|---|
| Revenue | $7.543M | $2.520M | $14.41M |
| YoY Change | -47.64% | 158.46% | 4161.83% |
| Cost Of Revenue | $1.810M | $505.0K | $430.0K |
| YoY Change | 320.93% | 1131.71% | |
| Gross Profit | -$126.8M | $2.015M | $12.19M |
| YoY Change | -1140.44% | 115.74% | |
| Gross Profit Margin | -1681.43% | 79.96% | 84.62% |
| Selling, General & Admin | $14.41M | $15.10M | $8.590M |
| YoY Change | 67.75% | 70.4% | 19.14% |
| % of Gross Profit | 749.58% | 70.47% | |
| Research & Development | $14.41M | $0.00 | $10.58M |
| YoY Change | 36.2% | -100.0% | 83.68% |
| % of Gross Profit | 0.0% | 86.79% | |
| Depreciation & Amortization | -$1.200M | $200.0K | $830.0K |
| YoY Change | -244.58% | 0.0% | 8200.0% |
| % of Gross Profit | 9.93% | 6.81% | |
| Operating Expenses | -$110.4M | $79.49M | $31.42M |
| YoY Change | -451.4% | 361.58% | 142.44% |
| Operating Profit | -$30.62M | -$31.80M | -$32.22M |
| YoY Change | -4.95% | 85.09% | 148.51% |
| Interest Expense | -$7.160M | $3.220M | -$2.000M |
| YoY Change | 258.0% | 367.34% | -18.37% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$3.704M | ||
| YoY Change | 421.69% | ||
| Pretax Income | -$23.70M | -$36.31M | -$21.30M |
| YoY Change | 11.27% | 114.07% | 41.25% |
| Income Tax | $1.513M | $0.00 | |
| % Of Pretax Income | |||
| Net Earnings | -$10.41M | -$27.12M | -$17.43M |
| YoY Change | -40.26% | 108.89% | 44.82% |
| Net Earnings / Revenue | -138.05% | -1076.03% | -121.01% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$226.7K | -$666.0K | -$433.7K |
| COMMON SHARES | |||
| Basic Shares Outstanding | 50.66M shares | 50.53M shares | 48.88M shares |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2017 Q4 | 2017 Q3 | 2016 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $131.0M | $156.2M | $90.70M |
| YoY Change | 44.43% | 84.42% | -7.64% |
| Cash & Equivalents | $94.95M | $128.5M | $105.2M |
| Short-Term Investments | $36.00M | $45.70M | $2.400M |
| Other Short-Term Assets | $43.60M | $11.70M | $10.10M |
| YoY Change | 331.68% | 108.93% | 531.25% |
| Inventory | $171.0K | $318.0K | $203.0K |
| Prepaid Expenses | |||
| Receivables | $7.758M | $5.582M | $1.830M |
| Other Receivables | $600.0K | $10.20M | $6.900M |
| Total Short-Term Assets | $183.2M | $184.1M | $109.6M |
| YoY Change | 67.08% | 86.7% | 9.7% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $7.116M | $2.397M | $7.376M |
| YoY Change | -3.52% | 105.93% | 2287.06% |
| Goodwill | $18.65M | $18.65M | $18.65M |
| YoY Change | 0.0% | -14.23% | |
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | $300.0K | $0.00 | $300.0K |
| YoY Change | 0.0% | -100.0% | 20.0% |
| Other Assets | $258.0K | $346.0K | $394.0K |
| YoY Change | -34.52% | 620.83% | 816.28% |
| Total Long-Term Assets | $62.77M | $61.00M | $61.10M |
| YoY Change | 2.74% | 30.29% | 227.19% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $183.2M | $184.1M | $109.6M |
| Total Long-Term Assets | $62.77M | $61.00M | $61.10M |
| Total Assets | $246.0M | $245.1M | $170.7M |
| YoY Change | 44.06% | 68.54% | 43.94% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $27.60M | $32.00M | $24.30M |
| YoY Change | 13.58% | 46.79% | 1200.86% |
| Accrued Expenses | $17.63M | $16.65M | $10.08M |
| YoY Change | 74.89% | 93.5% | 17.64% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $13.20M | $13.00M | $2.000M |
| YoY Change | 560.0% | ||
| Total Short-Term Liabilities | $71.44M | $68.43M | $56.57M |
| YoY Change | 26.29% | 77.31% | 434.69% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $49.30M | $50.70M | $26.20M |
| YoY Change | 88.17% | 85.04% | 12.93% |
| Other Long-Term Liabilities | $4.739M | $4.736M | $5.014M |
| YoY Change | -5.48% | 3.34% | 758.56% |
| Total Long-Term Liabilities | $4.739M | $4.736M | $5.014M |
| YoY Change | -5.48% | 3.34% | 758.56% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $71.44M | $68.43M | $56.57M |
| Total Long-Term Liabilities | $4.739M | $4.736M | $5.014M |
| Total Liabilities | $125.4M | $123.8M | $87.76M |
| YoY Change | 42.94% | 75.44% | 155.59% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$312.1M | -$301.7M | -$245.3M |
| YoY Change | 27.27% | 32.44% | 28.97% |
| Common Stock | $51.00K | $51.00K | $49.00K |
| YoY Change | 4.08% | 4.08% | 4.26% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $52.57M | $36.94M | $38.50M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $246.0M | $245.1M | $170.7M |
| YoY Change | 44.06% | 68.54% | 43.94% |
Cashflow Statement
| Concept | 2017 Q4 | 2017 Q3 | 2016 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$10.41M | -$27.12M | -$17.43M |
| YoY Change | -40.26% | 108.89% | 44.82% |
| Depreciation, Depletion And Amortization | -$1.200M | $200.0K | $830.0K |
| YoY Change | -244.58% | 0.0% | 8200.0% |
| Cash From Operating Activities | -$20.87M | -$25.08M | -$17.97M |
| YoY Change | 16.14% | 184.35% | -728.32% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | -$3.010M | -$550.0K | -$610.0K |
| YoY Change | 393.44% | -62.33% | 221.05% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $8.790M | -$24.29M | -$690.0K |
| YoY Change | -1373.91% | -770.99% | -102.34% |
| Cash From Investing Activities | $5.780M | -$24.83M | -$1.300M |
| YoY Change | -544.62% | -1249.54% | -104.44% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 20.66M | 17.14M | 25.96M |
| YoY Change | -20.42% | -4.03% | -35.84% |
| NET CHANGE | |||
| Cash From Operating Activities | -20.87M | -25.08M | -17.97M |
| Cash From Investing Activities | 5.780M | -24.83M | -1.300M |
| Cash From Financing Activities | 20.66M | 17.14M | 25.96M |
| Net Change In Cash | 5.570M | -32.77M | 6.690M |
| YoY Change | -16.74% | -392.59% | -90.79% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$20.87M | -$25.08M | -$17.97M |
| Capital Expenditures | -$3.010M | -$550.0K | -$610.0K |
| Free Cash Flow | -$17.86M | -$24.53M | -$17.36M |
| YoY Change | 2.88% | 233.29% | -669.18% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2017Q3 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
346000 | USD |
| CY2016Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
394000 | USD |
| CY2017Q3 | us-gaap |
Assets
Assets
|
245091000 | USD |
| CY2016Q4 | us-gaap |
Assets
Assets
|
170731000 | USD |
| CY2017Q3 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
161000 | USD |
| CY2016Q4 | us-gaap |
Interest Payable Current
InterestPayableCurrent
|
88000 | USD |
| CY2017Q3 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
68428000 | USD |
| CY2016Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
56565000 | USD |
| CY2017Q3 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
4736000 | USD |
| CY2016Q4 | us-gaap |
Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
|
5014000 | USD |
| CY2017Q3 | us-gaap |
Liabilities
Liabilities
|
123826000 | USD |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
87763000 | USD |
| CY2017Q3 | us-gaap |
Common Stock Value
CommonStockValue
|
51000 | USD |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
49000 | USD |
| CY2017Q3 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
338254000 | USD |
| CY2016Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
283697000 | USD |
| CY2017Q3 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-301714000 | USD |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-245251000 | USD |
| CY2017Q3 | us-gaap |
Stockholders Equity
StockholdersEquity
|
36944000 | USD |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
38495000 | USD |
| CY2017Q3 | us-gaap |
Minority Interest
MinorityInterest
|
84321000 | USD |
| CY2016Q4 | us-gaap |
Minority Interest
MinorityInterest
|
44473000 | USD |
| CY2017Q3 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
121265000 | USD |
| CY2016Q4 | us-gaap |
Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
|
82968000 | USD |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
170731000 | USD |
| CY2017Q3 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
245091000 | USD |
| CY2017Q3 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
313000 | USD |
| CY2016Q4 | us-gaap |
Derivative Liabilities Current
DerivativeLiabilitiesCurrent
|
481000 | USD |
| CY2017Q3 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
5582000 | USD |
| CY2016Q4 | us-gaap |
Accounts Receivable Net Current
AccountsReceivableNetCurrent
|
1830000 | USD |
| CY2017Q3 | us-gaap |
Deposits With Clearing Organizations And Others Securities
DepositsWithClearingOrganizationsAndOthersSecurities
|
1040000 | USD |
| CY2016Q4 | us-gaap |
Deposits With Clearing Organizations And Others Securities
DepositsWithClearingOrganizationsAndOthersSecurities
|
1030000 | USD |
| CY2017Q3 | us-gaap |
Receivables From Brokers Dealers And Clearing Organizations
ReceivablesFromBrokersDealersAndClearingOrganizations
|
8282000 | USD |
| CY2016Q4 | us-gaap |
Receivables From Brokers Dealers And Clearing Organizations
ReceivablesFromBrokersDealersAndClearingOrganizations
|
3357000 | USD |
| CY2017Q3 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
1269000 | USD |
| CY2016Q4 | us-gaap |
Notes And Loans Receivable Net Current
NotesAndLoansReceivableNetCurrent
|
1712000 | USD |
| CY2017Q3 | us-gaap |
Investment Owned At Fair Value
InvestmentOwnedAtFairValue
|
1595000 | USD |
| CY2016Q4 | us-gaap |
Investment Owned At Fair Value
InvestmentOwnedAtFairValue
|
2357000 | USD |
| CY2017Q3 | us-gaap |
Inventory Net
InventoryNet
|
318000 | USD |
| CY2016Q4 | us-gaap |
Inventory Net
InventoryNet
|
203000 | USD |
| CY2017Q3 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
31978000 | USD |
| CY2016Q4 | us-gaap |
Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
|
23871000 | USD |
| CY2017Q3 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
11255000 | USD |
| CY2016Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
11940000 | USD |
| CY2017Q3 | us-gaap |
Financial Instruments Sold Not Yet Purchased At Fair Value
FinancialInstrumentsSoldNotYetPurchasedAtFairValue
|
0 | USD |
| CY2016Q4 | us-gaap |
Financial Instruments Sold Not Yet Purchased At Fair Value
FinancialInstrumentsSoldNotYetPurchasedAtFairValue
|
298000 | USD |
| CY2017Q3 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
4733000 | USD |
| CY2016Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
1031000 | USD |
| CY2017Q3 | fbio |
Contingently Issuable Liabilities Current
ContingentlyIssuableLiabilitiesCurrent
|
0 | USD |
| CY2016Q4 | fbio |
Contingently Issuable Liabilities Current
ContingentlyIssuableLiabilitiesCurrent
|
1682000 | USD |
| CY2017Q3 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
193000 | USD |
| CY2016Q4 | us-gaap |
Other Liabilities Current
OtherLiabilitiesCurrent
|
319000 | USD |
| CY2017Q3 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
9928000 | USD |
| CY2016Q4 | us-gaap |
Convertible Debt Fair Value Disclosures
ConvertibleDebtFairValueDisclosures
|
3656000 | USD |
| CY2017Q3 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2016Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
USD | |
| CY2017Q3 | us-gaap |
Short Term Investments
ShortTermInvestments
|
44088000 | USD |
| CY2016Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
0 | USD |
| CY2017Q3 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
88000 | USD |
| CY2016Q4 | us-gaap |
Due To Related Parties Current
DueToRelatedPartiesCurrent
|
0 | USD |
| CY2017Q3 | fbio |
Due To Related Parties Interest Expenses Current
DueToRelatedPartiesInterestExpensesCurrent
|
497000 | USD |
| CY2016Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-16246000 | USD |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-56463000 | USD | |
| fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-1800000 | USD | |
| CY2017Q3 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
15983000 | USD |
| CY2016Q4 | us-gaap |
Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
|
17408000 | USD |
| CY2017Q3 | us-gaap |
Goodwill
Goodwill
|
18645000 | USD |
| CY2016Q4 | us-gaap |
Goodwill
Goodwill
|
18645000 | USD |
| us-gaap |
Operating Expenses
OperatingExpenses
|
215638000 | USD | |
| us-gaap |
Operating Expenses
OperatingExpenses
|
50338000 | USD | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-73373000 | USD | |
| us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-46473000 | USD | |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
530000 | USD | |
| us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
241000 | USD | |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-445000 | USD | |
| CY2016Q4 | fbio |
Due To Related Parties Interest Expenses Current
DueToRelatedPartiesInterestExpensesCurrent
|
77000 | USD |
| CY2017Q3 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
353000 | USD |
| CY2016Q4 | us-gaap |
Common Stock Shares Subscriptions
CommonStockSharesSubscriptions
|
0 | USD |
| CY2017Q3 | us-gaap |
Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
|
638000 | USD |
| CY2016Q4 | us-gaap |
Due From Other Related Parties Current
DueFromOtherRelatedPartiesCurrent
|
1790000 | USD |
| CY2017Q3 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
10739000 | USD |
| CY2016Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
9061000 | USD |
| CY2017Q3 | us-gaap |
Assets Current
AssetsCurrent
|
184087000 | USD |
| us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-3515000 | USD | |
| us-gaap |
Profit Loss
ProfitLoss
|
-73818000 | USD | |
| us-gaap |
Profit Loss
ProfitLoss
|
-49988000 | USD | |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-17355000 | USD | |
| us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-12324000 | USD | |
| us-gaap |
Net Income Loss
NetIncomeLoss
|
-37664000 | USD | |
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-1.39 | ||
| us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.94 | ||
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
40547364 | shares | |
| us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
39885685 | shares | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
109634000 | USD |
| CY2017Q3 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
637000 | USD |
| CY2016Q4 | us-gaap |
Business Combination Contingent Consideration Liability Current
BusinessCombinationContingentConsiderationLiabilityCurrent
|
424000 | USD |
| CY2017Q3 | fbio |
Warrants Issuable Current
WarrantsIssuableCurrent
|
8832000 | USD |
| CY2016Q4 | fbio |
Warrants Issuable Current
WarrantsIssuableCurrent
|
14359000 | USD |
| fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-241000 | USD | |
| CY2017Q3 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
8221000 | USD |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
7376000 | USD |
| CY2017Q3 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
16886000 | USD |
| CY2016Q4 | us-gaap |
Restricted Cash And Cash Equivalents Noncurrent
RestrictedCashAndCashEquivalentsNoncurrent
|
15860000 | USD |
| CY2017Q3 | us-gaap |
Long Term Investments
LongTermInvestments
|
923000 | USD |
| CY2016Q4 | us-gaap |
Long Term Investments
LongTermInvestments
|
1414000 | USD |
| fbio |
Interestexpenseandfinancefees
Interestexpenseandfinancefees
|
5298000 | USD | |
| fbio |
Interestexpenseandfinancefees
Interestexpenseandfinancefees
|
1838000 | USD | |
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
-5155000 | USD | |
| us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
105000 | USD | |
| fbio |
Changeinfairvalueofsubsidiaryconvertiblenote
Changeinfairvalueofsubsidiaryconvertiblenote
|
-359000 | USD | |
| fbio |
Changeinfairvalueofsubsidiaryconvertiblenote
Changeinfairvalueofsubsidiaryconvertiblenote
|
-13000 | USD | |
| CY2017Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
79489000 | USD |
| CY2016Q3 | us-gaap |
Operating Expenses
OperatingExpenses
|
17221000 | USD |
| CY2017Q3 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-32603000 | USD |
| CY2017Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
204000 | USD |
| CY2016Q3 | us-gaap |
Investment Income Interest
InvestmentIncomeInterest
|
89000 | USD |
| CY2017Q3 | fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
270000 | USD |
| CY2016Q3 | fbio |
Change In Fair Value Of Short Term Investments
ChangeInFairValueOfShortTermInvestments
|
-81000 | USD |
| CY2017Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-3704000 | USD |
| CY2016Q3 | us-gaap |
Nonoperating Income Expense
NonoperatingIncomeExpense
|
-710000 | USD |
| CY2017Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-36307000 | USD |
| CY2016Q3 | us-gaap |
Profit Loss
ProfitLoss
|
-16956000 | USD |
| CY2017Q3 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-9191000 | USD |
| CY2016Q3 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-3975000 | USD |
| CY2017Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-27116000 | USD |
| CY2016Q3 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-12981000 | USD |
| CY2017Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.67 | |
| CY2016Q3 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.32 | |
| CY2017Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
40724115 | shares |
| CY2016Q3 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
40128475 | shares |
| CY2017Q3 | fbio |
Interestexpenseandfinancefees
Interestexpenseandfinancefees
|
3220000 | USD |
| CY2016Q3 | fbio |
Interestexpenseandfinancefees
Interestexpenseandfinancefees
|
689000 | USD |
| CY2017Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
639000 | USD |
| CY2016Q3 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
16000 | USD |
| CY2017Q3 | fbio |
Changeinfairvalueofsubsidiaryconvertiblenote
Changeinfairvalueofsubsidiaryconvertiblenote
|
-74000 | USD |
| CY2016Q3 | fbio |
Changeinfairvalueofsubsidiaryconvertiblenote
Changeinfairvalueofsubsidiaryconvertiblenote
|
-13000 | USD |
| us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
0 | USD | |
| CY2017Q3 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
245000 | USD |
| CY2016Q3 | us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
0 | USD |
| us-gaap |
Other Nonoperating Expense
OtherNonoperatingExpense
|
232000 | USD | |
| CY2017Q3 | us-gaap |
Revenues
Revenues
|
46886000 | USD |
| CY2016Q3 | us-gaap |
Revenues
Revenues
|
975000 | USD |
| us-gaap |
Revenues
Revenues
|
142265000 | USD | |
| us-gaap |
Revenues
Revenues
|
3865000 | USD | |
| us-gaap |
Stock Issued During Period Value Restricted Stock Award Gross
StockIssuedDuringPeriodValueRestrictedStockAwardGross
|
0 | USD | |
| us-gaap |
Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition
|
12048000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital And Noncontrolling Interest From Subsidiary Equity Issuance
AdjustmentsToAdditionalPaidInCapitalAndNoncontrollingInterestFromSubsidiaryEquityIssuance
|
0 | USD | |
| fbio |
Adjustments To Additional Paid In Capital Stock Issued For License Expenses
AdjustmentsToAdditionalPaidInCapitalStockIssuedForLicenseExpenses
|
1762000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital Subsidiary Public Offering
AdjustmentsToAdditionalPaidInCapitalSubsidiaryPublicOffering
|
94645000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital Debt Discount Related To Opus Credit Facility
AdjustmentsToAdditionalPaidInCapitalDebtDiscountRelatedToOpusCreditFacility
|
201000 | USD | |
| us-gaap |
Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
|
750000 | USD | |
| us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
27000 | USD | |
| us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
42000 | USD | |
| fbio |
Adjustments To Additional Paid In Capital Warrants Issued In Connection With Promissory Notes
AdjustmentsToAdditionalPaidInCapitalWarrantsIssuedInConnectionWithPromissoryNotes
|
1784000 | USD | |
| us-gaap |
Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
|
314000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
-288000 | USD | |
| us-gaap |
Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
|
3948000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-61480000 | USD | |
| us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-27842000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
999000 | USD | |
| us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
5756000 | USD | |
| us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
0 | USD | |
| us-gaap |
Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
|
350000 | USD | |
| us-gaap |
Proceeds From Other Deposits
ProceedsFromOtherDeposits
|
42000 | USD | |
| us-gaap |
Proceeds From Other Deposits
ProceedsFromOtherDeposits
|
0 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-46001000 | USD | |
| us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
-4755000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
1426000 | USD | |
| us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
797000 | USD | |
| us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
22000 | USD | |
| us-gaap |
Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
|
41000 | USD | |
| us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
3143000 | USD | |
| fbio |
Payment For Research And Development Licenses
PaymentForResearchAndDevelopmentLicenses
|
965000 | USD | |
| fbio |
Payment For Research And Development Licenses
PaymentForResearchAndDevelopmentLicenses
|
3095000 | USD | |
| us-gaap |
Research And Development Asset Acquired Other Than Through Business Combination Written Off
ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
|
3394000 | USD | |
| us-gaap |
Cost Of Goods Sold Amortization
CostOfGoodsSoldAmortization
|
401000 | USD | |
| us-gaap |
Cost Of Goods Sold Amortization
CostOfGoodsSoldAmortization
|
50000 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
3752000 | USD | |
| us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
118000 | USD | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
115000 | USD | |
| us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
123000 | USD | |
| us-gaap |
Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
|
-1152000 | USD | |
| us-gaap |
Increase Decrease Due From Other Related Parties
IncreaseDecreaseDueFromOtherRelatedParties
|
1389000 | USD | |
| us-gaap |
Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
|
0 | USD | |
| us-gaap |
Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
|
175000 | USD | |
| fbio |
Amortization Of Forgivable Loans To Registered Representatives
AmortizationOfForgivableLoansToRegisteredRepresentatives
|
520000 | USD | |
| fbio |
Amortization Of Forgivable Loans To Registered Representatives
AmortizationOfForgivableLoansToRegisteredRepresentatives
|
0 | USD | |
| fbio |
Amortization Of Deferred Clearing Credit
AmortizationOfDeferredClearingCredit
|
-157000 | USD | |
| fbio |
Amortization Of Deferred Clearing Credit
AmortizationOfDeferredClearingCredit
|
0 | USD | |
| us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
274000 | USD | |
| us-gaap |
Allowance For Doubtful Accounts Receivable Recoveries
AllowanceForDoubtfulAccountsReceivableRecoveries
|
0 | USD | |
| fbio |
Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
|
-5155000 | USD | |
| fbio |
Change In Fair Value Of Contingently Issuable Warrants
ChangeInFairValueOfContingentlyIssuableWarrants
|
105000 | USD | |
| us-gaap |
Increase Decrease In Broker Dealer Related Receivables Payables Net
IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet
|
4925000 | USD | |
| us-gaap |
Increase Decrease In Broker Dealer Related Receivables Payables Net
IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet
|
0 | USD | |
| us-gaap |
Increase Decrease In Other Loans
IncreaseDecreaseInOtherLoans
|
77000 | USD | |
| us-gaap |
Increase Decrease In Other Loans
IncreaseDecreaseInOtherLoans
|
0 | USD | |
| us-gaap |
Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
|
-762000 | USD | |
| us-gaap |
Increase Decrease In Marketable Securities Restricted
IncreaseDecreaseInMarketableSecuritiesRestricted
|
0 | USD | |
| us-gaap |
Increase Decrease In Financial Instruments Sold Not Yet Purchased
IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased
|
-298000 | USD | |
| us-gaap |
Increase Decrease In Financial Instruments Sold Not Yet Purchased
IncreaseDecreaseInFinancialInstrumentsSoldNotYetPurchased
|
0 | USD | |
| us-gaap |
Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
|
430000 | USD | |
| us-gaap |
Increase Decrease In Due To Other Related Parties Current
IncreaseDecreaseInDueToOtherRelatedPartiesCurrent
|
0 | USD | |
| us-gaap |
Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
|
19000 | USD | |
| us-gaap |
Payments For Proceeds From Businesses And Interest In Affiliates
PaymentsForProceedsFromBusinessesAndInterestInAffiliates
|
-4626000 | USD | |
| us-gaap |
Depreciation
Depreciation
|
819000 | USD | |
| us-gaap |
Depreciation
Depreciation
|
240000 | USD | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
1235000 | USD | |
| us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
0 | USD | |
| fbio |
Increase Decrease In Cash Deposits With Clearing Organisations
IncreaseDecreaseInCashDepositsWithClearingOrganisations
|
-10000 | USD | |
| fbio |
Increase Decrease In Cash Deposits With Clearing Organisations
IncreaseDecreaseInCashDepositsWithClearingOrganisations
|
0 | USD | |
| us-gaap |
Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
|
84000 | USD | |
| us-gaap |
Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
|
0 | USD | |
| us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
44088000 | USD | |
| us-gaap |
Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
|
0 | USD | |
| us-gaap |
Payments For Mortgage Deposits
PaymentsForMortgageDeposits
|
5000 | USD | |
| us-gaap |
Payments For Mortgage Deposits
PaymentsForMortgageDeposits
|
0 | USD | |
| us-gaap |
Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
|
28000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
4195000 | USD | |
| us-gaap |
Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
|
5364000 | USD | |
| fbio |
Change In Fair Value Of Subsidiaries Assets And Liabilities
ChangeInFairValueOfSubsidiariesAssetsAndLiabilities
|
1341000 | USD | |
| fbio |
Change In Fair Value Of Subsidiaries Assets And Liabilities
ChangeInFairValueOfSubsidiariesAssetsAndLiabilities
|
491000 | USD | |
| CY2017Q3 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
14756000 | USD |
| CY2017Q3 | us-gaap |
Depreciation
Depreciation
|
200000 | USD |
| CY2016Q3 | us-gaap |
Depreciation
Depreciation
|
200000 | USD |
| CY2014Q1 | us-gaap |
Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
|
0.35 | pure |
| CY2016Q4 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
300000 | USD |
| us-gaap |
Investments In And Advances To Affiliates At Fair Value Period Increase Decrease
InvestmentsInAndAdvancesToAffiliatesAtFairValuePeriodIncreaseDecrease
|
200000 | USD | |
| CY2016Q4 | fbio |
Equity Securities Called By Warrant
EquitySecuritiesCalledByWarrant
|
10000 | USD |
| CY2016Q4 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
1414000 | USD |
| CY2016Q4 | us-gaap |
Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
|
1414000 | USD |
| CY2016Q4 | us-gaap |
Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
|
5168000 | USD |
| CY2017Q3 | us-gaap |
Investments Fair Value Disclosure
InvestmentsFairValueDisclosure
|
923000 | USD |
| CY2017Q3 | us-gaap |
Assets Fair Value Disclosure Recurring
AssetsFairValueDisclosureRecurring
|
923000 | USD |
| CY2017Q3 | us-gaap |
Liabilities Fair Value Disclosure Recurring
LiabilitiesFairValueDisclosureRecurring
|
14974000 | USD |
| CY2016Q4 | us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Value
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetValue
|
20941000 | USD |
| fbio |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Derivative Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisDerivativeLiabilityGainLossIncludedInEarnings
|
5155000 | USD | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
|
359000 | USD | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Gain Loss Included In Earnings1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetGainLossIncludedInEarnings1
|
241000 | USD | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetIssues
|
0 | USD | |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Issues
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityIssues
|
1064000 | USD | |
| us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
3394000 | USD | |
| us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
3143000 | USD | |
| CY2017Q3 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
300000 | USD |
| CY2016Q3 | us-gaap |
Research And Development In Process
ResearchAndDevelopmentInProcess
|
1000000 | USD |
| CY2017Q3 | us-gaap |
Long Term Debt
LongTermDebt
|
67445000 | USD |
| CY2016Q4 | us-gaap |
Long Term Debt
LongTermDebt
|
30224000 | USD |
| CY2017Q3 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
3827000 | USD |
| CY2016Q4 | us-gaap |
Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
|
2009000 | USD |
| CY2017Q3 | us-gaap |
Notes Payable
NotesPayable
|
63618000 | USD |
| CY2016Q4 | us-gaap |
Notes Payable
NotesPayable
|
28215000 | USD |
| us-gaap |
Interest Expense
InterestExpense
|
5298000 | USD | |
| us-gaap |
Interest Expense
InterestExpense
|
1838000 | USD | |
| CY2017Q3 | us-gaap |
Interest Expense
InterestExpense
|
3220000 | USD |
| CY2016Q3 | us-gaap |
Interest Expense
InterestExpense
|
689000 | USD |
| CY2017Q3 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
4178000 | USD |
| CY2016Q4 | us-gaap |
Accrued Salaries Current
AccruedSalariesCurrent
|
2846000 | USD |
| CY2017Q3 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1297000 | USD |
| CY2016Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1253000 | USD |
| CY2017Q3 | fbio |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
3311000 | USD |
| CY2016Q4 | fbio |
Accrued Research And Development Expenses
AccruedResearchAndDevelopmentExpenses
|
394000 | USD |
| CY2017Q3 | fbio |
Other Short Term Liabilities Related To Manufacturing Rights
OtherShortTermLiabilitiesRelatedToManufacturingRights
|
0 | USD |
| CY2016Q4 | fbio |
Other Short Term Liabilities Related To Manufacturing Rights
OtherShortTermLiabilitiesRelatedToManufacturingRights
|
900000 | USD |
| CY2017Q3 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2703000 | USD |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
2002000 | USD |
| CY2017Q3 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
16651000 | USD |
| CY2016Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
10082000 | USD |
| CY2017Q3 | us-gaap |
Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
|
0 | USD |
| CY2017Q3 | fbio |
Accrued Expenses Releted To Dr Falk Pharma Milestone
AccruedExpensesReletedToDrFalkPharmaMilestone
|
2950000 | USD |
| CY2016Q4 | fbio |
Accrued Expenses Releted To Dr Falk Pharma Milestone
AccruedExpensesReletedToDrFalkPharmaMilestone
|
2634000 | USD |
| CY2017Q3 | fbio |
Deferred Rent And Long Term Lease Abandonment Non Current
DeferredRentAndLongTermLeaseAbandonmentNonCurrent
|
4736000 | USD |
| CY2016Q4 | fbio |
Deferred Rent And Long Term Lease Abandonment Non Current
DeferredRentAndLongTermLeaseAbandonmentNonCurrent
|
5014000 | USD |
| CY2016Q4 | us-gaap |
Supplemental Unemployment Benefits Severance Benefits
SupplementalUnemploymentBenefitsSeveranceBenefits
|
53000 | USD |
| us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
101676000 | USD | |
| CY2016 | us-gaap |
Minority Interest Period Increase Decrease
MinorityInterestPeriodIncreaseDecrease
|
60668000 | USD |
| CY2016 | us-gaap |
Net Income Loss Attributable To Noncontrolling Interest
NetIncomeLossAttributableToNoncontrollingInterest
|
-16195000 | USD |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13063630 | shares | |
| us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
13767873 | shares | |
| CY2017Q3 | fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
52000 | USD |
| CY2016Q3 | fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
35000 | USD |
| fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
100000 | USD | |
| fbio |
Employee Stock Purchase Plan Compensation Expense Recognized
EmployeeStockPurchasePlanCompensationExpenseRecognized
|
91000 | USD | |
| fbio |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedGrantedWeightedAverageRemainingContractualTerm
|
P9Y6M22D | ||
| fbio |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm
|
P9Y6M22D | ||
| CY2017Q1 | fbio |
Warrants Issued
WarrantsIssued
|
853677 | shares |
| fbio |
Lease Sharing Agreements Contributions To Property Under Lease
LeaseSharingAgreementsContributionsToPropertyUnderLease
|
300000 | USD | |
| fbio |
Annual Management Services Agreement Fee Incomeexpense
AnnualManagementServicesAgreementFeeIncomeexpense
|
0 | USD | |
| CY2017Q3 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
50584937 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
50584937 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
48932023 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
48932023 | shares |
| CY2017Q3 | us-gaap |
Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
|
86272 | shares |
| CY2016Q4 | us-gaap |
Common Stock Shares Subscribed But Unissued
CommonStockSharesSubscribedButUnissued
|
0 | shares |
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
353000 | USD | |
| us-gaap |
Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
|
0 | USD | |
| us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
11652000 | USD | |
| us-gaap |
Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
|
94645000 | USD | |
| fbio |
Proceeds From Issuance Of At Market Offering
ProceedsFromIssuanceOfAtMarketOffering
|
0 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
27000 | USD | |
| fbio |
Proceeds From Issuance Of At Market Offering
ProceedsFromIssuanceOfAtMarketOffering
|
434000 | USD | |
| fbio |
Payment Of Cost Related To Atthemarket Offering
PaymentOfCostRelatedToAtthemarketOffering
|
0 | USD | |
| fbio |
Payment Of Cost Related To Atthemarket Offering
PaymentOfCostRelatedToAtthemarketOffering
|
49000 | USD | |
| us-gaap |
Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
|
28355000 | USD | |
| us-gaap |
Proceeds From Unsecured Notes Payable
ProceedsFromUnsecuredNotesPayable
|
0 | USD | |
| us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
1081000 | USD | |
| us-gaap |
Payments Of Financing Costs
PaymentsOfFinancingCosts
|
0 | USD | |
| fbio |
Payment Of Nsc Note
PaymentOfNscNote
|
3608000 | USD | |
| fbio |
Payment Of Nsc Note
PaymentOfNscNote
|
2792000 | USD | |
| us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | USD | |
| fbio |
Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan
|
42000 | USD | |
| fbio |
Proceeds From Issuance Of Common Stock Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockEmployeeStockPurchasePlan
|
81000 | USD | |
| us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
9914000 | USD | |
| us-gaap |
Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
|
3018000 | USD | |
| us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
1071000 | USD | |
| us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
392000 | USD | |
| us-gaap |
Proceeds From Unsecured Lines Of Credit
ProceedsFromUnsecuredLinesOfCredit
|
2500000 | USD | |
| us-gaap |
Proceeds From Unsecured Lines Of Credit
ProceedsFromUnsecuredLinesOfCredit
|
5000000 | USD | |
| us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
0 | USD | |
| us-gaap |
Proceeds From Notes Payable
ProceedsFromNotesPayable
|
920000 | USD | |
| us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
0 | USD | |
| us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
-920000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
129723000 | USD | |
| us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
16952000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
22242000 | USD | |
| us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-15645000 | USD | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
98182000 | USD |
| CY2016Q3 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
82537000 | USD |
| us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
2000 | USD | |
| us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
2000 | USD | |
| fbio |
Issuance Of Warrants In Conjunction With Nsc Debt
IssuanceOfWarrantsInConjunctionWithNscDebt
|
634000 | USD | |
| fbio |
Issuance Of Warrants In Conjunction With Nsc Debt
IssuanceOfWarrantsInConjunctionWithNscDebt
|
750000 | USD | |
| fbio |
Promissory Notes Conversion Converted Instrument Amount
PromissoryNotesConversionConvertedInstrumentAmount
|
1784000 | USD | |
| fbio |
Promissory Notes Conversion Converted Instrument Amount
PromissoryNotesConversionConvertedInstrumentAmount
|
0 | USD | |
| fbio |
Convertible Notes Conversion Converted Instrument Amount
ConvertibleNotesConversionConvertedInstrumentAmount
|
201000 | USD | |
| fbio |
Convertible Notes Conversion Converted Instrument Amount
ConvertibleNotesConversionConvertedInstrumentAmount
|
0 | USD | |
| fbio |
Issue Of Common Stock For Acquiring License Value
IssueOfCommonStockForAcquiringLicenseValue
|
1682000 | USD | |
| fbio |
Issue Of Common Stock For Acquiring License Value
IssueOfCommonStockForAcquiringLicenseValue
|
0 | USD | |
| us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
314000 | USD | |
| us-gaap |
Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
|
0 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
|
4626000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Net Nonmonetary Assets Acquired Liabilities Assumed1
NoncashOrPartNoncashAcquisitionNetNonmonetaryAssetsAcquiredLiabilitiesAssumed1
|
0 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Net Nonmonetary Identifiable Intangible Assets Acquired Liabilities Assumed
NoncashOrPartNoncashAcquisitionNetNonmonetaryIdentifiableIntangibleAssetsAcquiredLiabilitiesAssumed
|
19000 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Net Nonmonetary Identifiable Intangible Assets Acquired Liabilities Assumed
NoncashOrPartNoncashAcquisitionNetNonmonetaryIdentifiableIntangibleAssetsAcquiredLiabilitiesAssumed
|
0 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
|
211000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Intangible Assets Acquired1
NoncashOrPartNoncashAcquisitionIntangibleAssetsAcquired1
|
0 | USD | |
| CY2017Q3 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
0 | USD |
| us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><b><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">Use of Estimates</font></b></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">  </font></div> <div style="CLEAR:both;LINE-HEIGHT: normal; MARGIN: 0in 0in 0pt; FONT-FAMILY: Calibri,sans-serif; FONT-SIZE: 11pt" align="justify"><font style="FONT-FAMILY: 'Times New Roman',serif; FONT-SIZE: 10pt">The Company’s unaudited condensed consolidated financial statements include certain amounts that are based on management’s best estimates and judgments. The Company’s significant estimates include, but are not limited to, useful lives assigned to long-lived and intangible assets, fair value measurements, stock-based compensation, common stock issued to acquire licenses, investments, accrued expenses, derivative warrant liabilities, provisions for income taxes and contingencies. Due to the uncertainty inherent in such estimates, actual results may differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table> | ||
| CY2016Q4 | us-gaap |
Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
|
15991000 | USD |
| CY2017Q3 | fbio |
Property Plant And Equipment Design Costs Capitalized
PropertyPlantAndEquipmentDesignCostsCapitalized
|
100000 | USD |
| CY2017Q2 | us-gaap |
Debt Conversion Converted Instrument Shares Issued1
DebtConversionConvertedInstrumentSharesIssued1
|
49749 | shares |
| CY2017Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
4.02 | |
| CY2017Q2 | fbio |
Exercise Price Of Warrant Discount Percentage
ExercisePriceOfWarrantDiscountPercentage
|
0.33 | pure |
| us-gaap |
Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Purchases
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetPurchases
|
10139000 | USD | |
| us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
250000 | USD | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
602451000 | USD |
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P4Y11M5D | |
| us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
20000 | shares | |
| us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
1.37 | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
|
61000000 | USD | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
3.78 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
1130501 | shares |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
|
3.73 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
|
1100501 | shares |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
|
1620046000 | USD |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
|
P4Y2M5D | ||
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
1085501 | shares |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
3.75 | |
| CY2017Q3 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
|
1620046000 | USD |
| us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
|
P4Y2M16D | ||
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.07 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0188 | pure | |
| us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0222 | pure | |
| us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
189000 | USD | |
| us-gaap |
Paid In Kind Interest
PaidInKindInterest
|
0 | USD | |
| us-gaap |
Impairment Of Investments
ImpairmentOfInvestments
|
0 | USD | |
| us-gaap |
Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
|
1026000 | USD | |
| us-gaap |
Increase Decrease In Restricted Cash For Operating Activities
IncreaseDecreaseInRestrictedCashForOperatingActivities
|
0 | USD | |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
680000 | USD | |
| us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
0 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
345000 | USD | |
| us-gaap |
Interest Paid Net
InterestPaidNet
|
238000 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Goodwill
NoncashOrPartNoncashAcquisitionGoodwill
|
0 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Goodwill
NoncashOrPartNoncashAcquisitionGoodwill
|
-4889000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1
NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1
|
0 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Accounts Receivable Acquired1
NoncashOrPartNoncashAcquisitionAccountsReceivableAcquired1
|
1030000 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Receivables From Brokerdealers And Clearing Organizations
NoncashOrPartNoncashAcquisitionReceivablesFromBrokerdealersAndClearingOrganizations
|
0 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Receivables From Brokerdealers And Clearing Organizations
NoncashOrPartNoncashAcquisitionReceivablesFromBrokerdealersAndClearingOrganizations
|
-1607000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Investments Acquired1
NoncashOrPartNoncashAcquisitionInvestmentsAcquired1
|
0 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Investments Acquired1
NoncashOrPartNoncashAcquisitionInvestmentsAcquired1
|
2178000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Other Assets Acquired1
NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1
|
0 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Other Assets Acquired1
NoncashOrPartNoncashAcquisitionOtherAssetsAcquired1
|
1985000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
0 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
|
1132000 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Restricted Cash
NoncashOrPartNoncashAcquisitionRestrictedCash
|
0 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Restricted Cash
NoncashOrPartNoncashAcquisitionRestrictedCash
|
-353000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1
NoncashOrPartNoncashAcquisitionEmployeeBenefitLiabilitiesAssumed1
|
0 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Employee Benefit Liabilities Assumed1
NoncashOrPartNoncashAcquisitionEmployeeBenefitLiabilitiesAssumed1
|
14029000 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed
NoncashOrPartNoncashAcquisitionDeferredClearingAndMarketingCreditsAssumed
|
0 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Deferred Clearing And Marketing Credits Assumed
NoncashOrPartNoncashAcquisitionDeferredClearingAndMarketingCreditsAssumed
|
-1007000 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Other Liabilities Assumed1
NoncashOrPartNoncashAcquisitionOtherLiabilitiesAssumed1
|
707000 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Noncontrolling Interests
NoncashOrPartNoncashAcquisitionNoncontrollingInterests
|
0 | USD | |
| fbio |
Noncash Or Part Noncash Acquisition Noncontrolling Interests
NoncashOrPartNoncashAcquisitionNoncontrollingInterests
|
17717000 | USD | |
| CY2017Q3 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
505000 | USD |
| CY2017Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
2786000 | USD |
| CY2017Q3 | fbio |
Research And Development Expenses Including Intangible Assets
ResearchAndDevelopmentExpensesIncludingIntangibleAssets
|
16190000 | USD |
| CY2017Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
12318000 | USD |
| CY2016Q3 | us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
41000 | USD |
| CY2016Q3 | us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
1244000 | USD |
| CY2016Q3 | fbio |
Research And Development Expenses Including Intangible Assets
ResearchAndDevelopmentExpensesIncludingIntangibleAssets
|
8316000 | USD |
| CY2016Q3 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
7620000 | USD |
| us-gaap |
Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
|
0 | USD | |
| us-gaap |
Noncash Or Part Noncash Acquisition Payables Assumed1
NoncashOrPartNoncashAcquisitionPayablesAssumed1
|
6079000 | USD | |
| us-gaap |
Amortization Of Acquisition Costs
AmortizationOfAcquisitionCosts
|
21739000 | USD | |
| us-gaap |
Amortization Of Acquisition Costs
AmortizationOfAcquisitionCosts
|
0 | USD | |
| us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
192000 | USD | |
| us-gaap |
Business Combination Consideration Transferred1
BusinessCombinationConsiderationTransferred1
|
0 | USD | |
| CY2016Q3 | us-gaap |
Assets
Assets
|
145421000 | USD |
| us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
1852000 | USD | |
| us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
7663000 | USD | |
| fbio |
Research And Development Expenses Including Intangible Assets
ResearchAndDevelopmentExpensesIncludingIntangibleAssets
|
38077000 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
28827000 | USD | |
| us-gaap |
Cost Of Goods Sold
CostOfGoodsSold
|
365000 | USD | |
| us-gaap |
Selling And Marketing Expense
SellingAndMarketingExpense
|
4212000 | USD | |
| fbio |
Research And Development Expenses Including Intangible Assets
ResearchAndDevelopmentExpensesIncludingIntangibleAssets
|
24559000 | USD | |
| us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
21202000 | USD | |
| CY2017Q1 | fbio |
Warrants Issued
WarrantsIssued
|
6400 | shares |
| fbio |
Sharebased Compensation Arrangement By Sharebased Payment Other Than Options Forfeited Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentOtherThanOptionsForfeitedWeightedAverageRemainingContractualTerm
|
P0Y | ||
| dei |
Document Type
DocumentType
|
10-Q | ||
| dei |
Amendment Flag
AmendmentFlag
|
false | ||
| dei |
Document Period End Date
DocumentPeriodEndDate
|
2017-09-30 | ||
| dei |
Document Fiscal Year Focus
DocumentFiscalYearFocus
|
2017 | ||
| dei |
Document Fiscal Period Focus
DocumentFiscalPeriodFocus
|
Q3 | ||
| dei |
Entity Registrant Name
EntityRegistrantName
|
Fortress Biotech, Inc. | ||
| dei |
Entity Central Index Key
EntityCentralIndexKey
|
0001429260 | ||
| dei |
Current Fiscal Year End Date
CurrentFiscalYearEndDate
|
--12-31 | ||
| dei |
Entity Filer Category
EntityFilerCategory
|
Accelerated Filer | ||
| dei |
Trading Symbol
TradingSymbol
|
FBIO | ||
| CY2017Q4 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
50656503 | shares |
| CY2017Q3 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
8223000 | USD |
| CY2016Q4 | us-gaap |
Other Notes Payable Current
OtherNotesPayableCurrent
|
1000000 | USD |
| CY2017Q3 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
40734000 | USD |
| CY2016Q4 | us-gaap |
Long Term Notes Payable
LongTermNotesPayable
|
22528000 | USD |
| CY2017Q3 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
1277 | USD |
| CY2016Q4 | us-gaap |
Debt Instrument Unamortized Discount Current
DebtInstrumentUnamortizedDiscountCurrent
|
0 | USD |
| CY2017Q3 | us-gaap |
Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
|
2550 | USD |
| CY2016Q4 | us-gaap |
Debt Instrument Unamortized Discount Noncurrent
DebtInstrumentUnamortizedDiscountNoncurrent
|
2009 | USD |
| us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
50000 | USD | |
| us-gaap |
Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
|
0 | USD | |
| CY2017Q3 | fbio |
Short Term Investment Maximum Amount Per Institution
ShortTermInvestmentMaximumAmountPerInstitution
|
250000 | USD |
| CY2017Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
4183000 | USD |
| CY2016Q3 | us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
2903000 | USD |
| us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
11736000 | USD | |
| us-gaap |
Employee Benefits And Share Based Compensation
EmployeeBenefitsAndShareBasedCompensation
|
8792000 | USD | |
| CY2014Q1 | fbio |
Investment Write Down
InvestmentWriteDown
|
300000 | USD |
| fbio |
Common Shares Issuable For Interest Payable
CommonSharesIssuableForInterestPayable
|
353000 | USD | |
| fbio |
Stock Issued During Period Value Interest Expense
StockIssuedDuringPeriodValueInterestExpense
|
189000 | USD | |
| CY2017Q3 | us-gaap |
Deferred Revenue And Credits Current
DeferredRevenueAndCreditsCurrent
|
838000 | USD |
| CY2016Q4 | us-gaap |
Deferred Revenue And Credits Current
DeferredRevenueAndCreditsCurrent
|
995000 | USD |
| CY2017Q3 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
680000 | USD |
| CY2016Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
0 | USD |
| us-gaap |
Proceeds From Collection Of Notes Receivable
ProceedsFromCollectionOfNotesReceivable
|
0 | USD | |
| fbio |
Unpaid Debt Offering Cost
UnpaidDebtOfferingCost
|
42000 | USD | |
| fbio |
Unpaid Debt Offering Cost
UnpaidDebtOfferingCost
|
0 | USD | |
| fbio |
Non Cash Or Part Non Cash Acquisition Beneficial Conversion Feature Related To Opus Credit Facility
NonCashOrPartNonCashAcquisitionBeneficialConversionFeatureRelatedToOpusCreditFacility
|
0 | USD | |
| fbio |
Non Cash Or Part Non Cash Acquisition Beneficial Conversion Feature Related To Opus Credit Facility
NonCashOrPartNonCashAcquisitionBeneficialConversionFeatureRelatedToOpusCreditFacility
|
1881000 | USD | |
| CY2017Q3 | us-gaap |
Litigation Reserve Current
LitigationReserveCurrent
|
2212000 | USD |
| CY2016Q4 | us-gaap |
Litigation Reserve Current
LitigationReserveCurrent
|
0 | USD |
| CY2014Q1 | us-gaap |
Equity Method Investments
EquityMethodInvestments
|
300000 | USD |
| us-gaap |
Litigation Settlement Expense
LitigationSettlementExpense
|
2000000 | USD | |
| us-gaap |
Litigation Settlement Amount Awarded To Other Party
LitigationSettlementAmountAwardedToOtherParty
|
200000 | USD |
